Several studies have shown downregulation of MEG3 in human cancers, such as breast cancer (Zhang et al., 2016), liver cancer (Zheng et al., 2018), gliomas (Zhang et al., 2017), lung cancer (Wu et al., 2018), squamous cell carcinoma (Sahin et al., 2017), and gastrointestinal cancer (Sun et al., 2014). Here, MEG3 is linked to central nervous system cancer.